The practice of nuclear medicine (NM) in the Middle East region has experienced an important growth in the last 2 decades and has become crucial in providing healthcare to the region's population of about 395 million people. Even though there are some countries in which the services provided are limited to basic coverage of studies with 99m Tc and 131 I, most have well-established practices covering most of the available studies in this medical specialty; this is the case in for example, Iran, Israel, Kuwait, Saudi Arabia, and Turkey. According to data provided by the NM professionals in the 17 countries included in the present publication, which was collected by the International Atomic Energy Agency in 2015, the total number of gamma cameras in the region is 910 with an average of 2.3 gamma cameras per million inhabitants. Out of these, 107 cameras, or 12%, are SPECT/CT cameras. There are 194 operating PET/CT scanners, translating to one PET/CT scanner for 2.04 million people on average. The availability of PET/CT scanners in relation to population is the highest in Lebanon and Kuwait, with 2.2 and 1.7 scanners per million people, respectively. There is a total of 628 NM centers in the 17 countries, whereas most NM centers belong to the public healthcare system and in most of the countries are widely spread and not confined exclusively to capital cities. As for the radionuclide therapies, 131 I is used regularly in diagnostic workup as well as in therapeutic applications in all the countries included in this analysis. Only five countries have the capability of assembling 99 Mo-99m Tc generators (Egypt, Iran, Saudi Arabia, Israel, and Turkey), and cold kits are produced in several countries. Although there are no capabilities in the region to produce 99 Mo from nuclear reactors, a total of 46 cyclotrons are operated for production of PET radionuclides. The most widely used PET tracer in the region is 18 F-FDG followed by 18 F-NaF; concomitantly, the availability of 68 Ge-68 Ga generators is increasing and studies involving prostate-specific membrane antigen or DOTA-chelated peptides or both are performed in at least seven countries. Although therapeutic radionuclide agents are mostly imported from outside the region, this does not limit the availability of therapies with 90 Y, 153 Sm, 177 Lu, 131 I, 188 Re, and 89 Sr. Nevertheless, therapies based on alpha particle emitters are still largely not available in the region and are currently only available in Israel and Turkey. Regarding human resources, according to the data provided there are 1157 NM physicians, 1953 technologists, 586 medical physicists, and 173 radiopharmacists or radiochemists in the region. Approximately half of all available human resources are accounted for by Turkey. The region has great potential for expanding the applications of NM; this becomes especially important in view of the high prevalence of non-communicable diseases. Further increasing awareness of the clinical applications of NM in healthcare and strengthening technical and human capacities including the establishment of training programs for all professionals and disciplines in the field are recognized as key components in advancing the practice of NM in the Middle East. Semin Nucl Med 46:265-272 C 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
M iddle East is one of the most dynamic regions in the world. Characterized by a unique combination of cultures, the region is experiencing rapid demographic and socioeconomic changes. With its fast growing population, http://dx.doi.org/10.1053/j.semnuclmed.2016.01.005 capacity building, and expansion of medical services are of high priority in this region. In this article, we apply the geographical rather than the political principle in defining the region, while also considering the status of nuclear medicine (NM) in terms of equipment, human resources, availability of radiopharmaceuticals, and type of diagnostic and therapeutic procedures performed. Although there is no unique definition of the region of Middle East and it varies from one source to another, the authors considered the inclusion of the countries specified below to be important for the purpose of this issue of the Seminars in Nuclear Medicine: Contributions to Nuclear Medicine from the Middle East. Accordingly, we provide analysis of the situation in Bahrain, Republic of Cyprus (in further text as Cyprus), Arab Republic of Egypt (in further text as Egypt), Islamic Republic of Iran (in further text as Iran), Iraq, Israel, Jordan, Kuwait, Lebanon, Oman, Palestinian Territory (in further text as Palestine), Qatar, Saudi Arabia, Syrian Arab Republic (in further text as Syria), Turkey, United Arab Emirates (in further text as UAE), and Yemen.
Human resources and availability of technology along with the production and supply of radiopharmaceuticals play a critical role in ensuring high quality of NM practice. This article provides information regarding the status of NM instruments, professionals, training programs, production and supply of radiopharmaceuticals, and future trends and needs in the region and can serve as an incentive to strengthen the practice of NM.
Demographic Data
Egypt is the most populous country with about 83 million people in 2014, followed by Iran with roughly 79 million inhabitants and Turkey with an approximate population of 76 million people. The population of Cyprus is the smallest, comprising 1.15 million people, followed by Bahrain with 1.34 million. 1 The total population of the region is 395 million people, and is projected to increase by 140 million people in the next 25 years, reaching 529 million. 2 Saudi Arabia encompasses the largest territory in the region, whereas Iran and Egypt take the second and third place, respectively. 1 The median age of the population was set at between 19.1 years in Yemen and 35.2 years in Cyprus. 3 Great economic disparities exist between the countries. Table 1 demonstrates some demographic characteristics of the Middle Eastern countries. Table 2 shows the wide range of life expectancy at birth. The average of 75 years as well as life expectancy in most of the countries individually was higher than the world average of 71 years. Adult mortality rate was lowest in Kuwait (52 per 1000 population), and highest in Yemen (232 per 1000 population). 3 Cardiovascular diseases (CVDs), cancers, diabetes, and chronic respiratory diseases as main non-communicable diseases (NCDs) are associated with a probability of premature death varying between 9% in Cyprus and Israel and 25% in Egypt. 4 Risk factors for NCDs (Table 3) are present in a large percentage of population in the region. Obesity represents a big challenge and affects as much as 50% of all adult women and 42% of the total adult population in Kuwait (2008) . In Lebanon, one-third of all adult men and 29% of the country's adult population suffer from raised blood pressure (2008). 4 An estimated 17% of Egypt's adult population was diagnosed with elevated fasting blood glucose. 3 The NCDs account for a great portion of total mortality in the region and are responsible for 4 With already high prevalence of NCDs and the associated mortality, as well as because negative health trends such as ever growing obesity rates threaten to worsen the situation and overburden the healthcare systems in the future, identifying appropriate management strategies is of utmost importance. As NM plays a crucial role in the diagnosis, risk stratification and management of most NCDs, its practice in the region should be up-scaled for efficient and cost-effective management of these diseases.
Health Indicators

Available Technology
There is great heterogeneity as to the availability of technical capacities in the region with some countries having state-ofthe-art technology including cyclotrons and PET/CT. According to data provided to the International Atomic Energy Agency (IAEA) in 2015 by NM professionals in the region, the total number of gamma cameras available is 910 including 107 SPECT/CT systems with Turkey, Iran, Israel, and Saudi Arabia having 310/12, 200/8, 63/26, and 49/34 SPECT/ SPECT-CT systems, respectively ( Table 4 ). The ratio of gamma cameras per million population ranges between 0.1 in Iraq and Bahrain  26  13  13  6  20  78  Cyprus  38  24  7  5  16  90  Egypt  46  14  1  4  19  85  Iran  46  13  2  4  11  76  Iraq  33  10  4  3  12  62  Israel  26  27  6  5  22  86  Jordan  35  15  7  3  16  76  Kuwait  41  14  4  2  12  73  Lebanon  47  22  4  4  8  85  Oman  33  10  10  2  13  68  Qatar  24  18  9  1  17  69  Saudi  Arabia   46  10  5  3  14  78   Syria  28  10  1  2  5  46  Turkey  47  22  2  8  7  86  UAE  30  13  3  3  16  65  Yemen  21  5  2  3  8 (Table 4 ). Most NM centers are part of the public healthcare system and are generally widely spread across the country and not only confined to capital or major cities. Regarding the availability of cyclotrons for production of PET radioisotopes (Table 4 ), there are currently 46 operative cyclotrons in the region devoted mainly to the production of 18 F; in addition, Israel, Lebanon, Turkey, Saudi Arabia, and Syria have capabilities to produce 11 C. The availability of 68 Ge-68 Ga generators is augmenting and countries such as Iran, Israel, Jordan, Kuwait, Lebanon, Saudi Arabia, and Turkey already perform studies with prostate-specific membrane antigen or DOTA-chelated peptides or both.
Human Resources and Education
NM Physicians
In many countries of the region, NM is a specialty obtained by physicians after an MD degree in 4-5 years. The introduction of hybrid imaging modalities for example, SPECT/CT and PET/ CT has attracted radiologists to the field of NM. There are approximately 1157 NM physicians in the region (Table 5) ; the number of physicians per equipment including SPECT and PET varies between 0.4 in Lebanon and 2.2 in Iraq ( Fig.) .
Radiopharmacists or Radiochemists
Albeit the scarce number of radiopharmacists or radiochemists in the region, the NM specialty has grown in the last 2 decades. In total, there are approximately 173 professionals with training in these disciplines (Table 5 ), in most of the cases obtained abroad. However, with growing research and development infrastructure in some countries the need for training scholars with highest academic degrees has been brought about, and in certain countries for example, Iran and Turkey academic training programs in radiopharmacy or radiochemistry already exist at PhD level. To fulfill the need for sustainable services at hospital radiopharmacy facilities, degrees at technician level in radiopharmacy or radiochemistry or onsite training for individuals who have obtained basic science degrees have been established in many countries.
Medical Physicists
According to the definition of the IAEA's International Basic Safety Standards, 5 a medical physicist working in a clinical environment is: "a health professional, with specialist education and training in the concepts and techniques of applying physics in medicine, and competent to practice independently in one or more of the subfields (specialties) of medical physics." In the field of NM their role is pivotal, they usually participate in several tasks, 6 such as the establishment of institutional radiation protection programs, quality control of NM instruments, and optimization of NM clinical procedures, including acquisition and processing protocols. Moreover, because of the increasing number of cases of radionuclide therapy in different clinical centers in the region, personalized clinical dosimetry in medical practice has strengthened their roles. According to the *This PET/CT is installed at the "Near East University" Nicosia, North Cyprus and due to absence of information on the remaining infrastructure of this center, it is not included in the overall statistical analysis.
information provided by the different countries there are 586 medical physicists working in the field of NM in the region ( Table 5) , some of them also providing support to radiotherapy departments.
Technologists
Like in other parts of the world, the shortage of technologists is a common problem in the region. The total number of technologists approximates to 1953 (Table 5) , and the availability per camera (including SPECT and PET scanners) varies between 0.9 in Israel and 3.6 in Kuwait ( Fig.) . The high ratio in Kuwait is partly due to the fact that technologists in the country do not provide support only to NM procedures, but rather to all diagnostic imaging modalities. Training programs for technologists in NM are available in the form of a Bachelor's degree in Egypt, Iran, Jordan, Kuwait, and Turkey and Masters in Science degree in Israel, whereas other countries mostly rely on onsite training. In most cases, the training is not focused on NM only but covers other areas of radiation medicine such as radiology and radiotherapy. In addition, technologist positions are frequently occupied by licensed biologists or laboratory technicians.
Types of Procedures and Availability of Radiopharmaceuticals
The availability of diagnostic and therapeutic radiopharmaceuticals in the region is heterogeneous (Tables 6 and 7) . Regarding radiopharmaceuticals used for SPECT imaging, all countries have 99 Mo-99m Tc generators, although only Egypt, Iran, Israel, Saudi Arabia, and Turkey have the capabilities of assembling the generators. 131 I is widely accessible for both diagnostic and therapeutic purposes. Despite the overall presence of PET scanners in the region, 67 Ga citrate is still being used in most of the countries (Table 6 ). Studies performed with 111 In for evaluation of infection and neuroendocrine tumors, among other indications, are performed in all the countries other than Cyprus, Iraq, Palestine, and Yemen. Data obtained from the IAEA Nuclear Medicine Database (NUMDAB), 7 which represents about 15% of all NM departments in the region, show that nearly 80% of procedures performed in a typical setting are diagnostic NM procedures, excluding PET/CT. As in other regions, bone and cardiac studies are the most common procedures performed, accounting for 30% and 20% of the total studies, respectively, followed by endocrine and renal studies. However, there is increased use of therapeutic agents such as somatostatin peptide analogs labeled with 177 Lu or 90 Y for neuroendocrine tumors and 90 Y-labeled anti-CD20 monoclonal antibodies for lymphoma. As for PET radioisotopes, 18 F is produced in the 13 countries which have operating cyclotrons (Table 4 ), 18 F-FDG being the most commonly used tracer, followed by 18 F-NaF. Israel, Lebanon, Turkey, Saudi Arabia, and Syria perform studies with 11 C ( Table 6 ). Concomitantly, the availability of 68 Ge-68 Ga generators is increasing and studies involving prostate-specific membrane antigen or DOTA-chelated peptides or both are performed in Iran, Israel, Jordan, Kuwait, Lebanon, Saudi Arabia, and Turkey. 13 N and the tracer 13 N-NH 3 are used in Israel, Jordan, Kuwait, Lebanon, Qatar, Saudi Arabia, and UAE; whereas 82 Sr-82 Rb generators are being used in Jordan, Kuwait, and Saudi Arabia. Cardiac studies with 201 Tl are still performed in many centers across the region (Table 6 ). In general, according to the IAEA NUMDAB, 7 PET applications currently represent about 16% of total NM studies performed in the region. Regarding radionuclide therapies, as indicated in Table 7 
Production and Distribution of Radiopharmaceuticals
From the technical point of view, radiolabeling, quality assurance, dispensing, and packaging of the radiopharmaceuticals also differs from one country to another. Iran, Israel, and Turkey have the most developed capacities for production and distribution. Various international companies from outside the region such as Nordion, Mallinckrodt, Polatom, and Izotop are active in the Middle East; this combined with the presence of regional companies such as Monrol and Pars Isotope ensures the wide availability of radiotracers and all NM procedures, both in diagnostic SPECT and PET imaging as well as in the therapeutic area. The activity of these commercial companies not only has fulfilled the existing demand of the region, but has also increased the rate of development and cost-effectiveness of procedures.
Cold Kit Laboratories
As the most important source of radiopharmaceuticals, 99m Tc cold kits still play an essential role in the NM practice and some member states in the region have developed stable and sustainable cold kit preparation units in the last 3 decades.
Apart from the simple small molecule kits, recently many biomolecular kits have been introduced and entered the clinical trials in the regions' countries such as peptide and antibody kits, owing to the existing infrastructure as well as a result of different IAEA initiatives. 8 
Research and Development
As mentioned earlier, the availability of qualified human resources as well as the existence of radionuclide production infrastructure including cyclotrons of various particle Table 6 List of Available Diagnostic Tracers in the Region, Data Obtained From Nuclear Medicine Professionals accelerating energies, research reactors and laboratories, has enabled the production of a variety of radioisotopes and radiopharmaceuticals. These developments have made it possible to move beyond the classical PET radiotracers produced in small medical cyclotrons, allowing 13 N-NH3 and in some cases 11 C tracers to be produced. The operation of cyclotron machines with more than 25 MeV accelerated protons not only led to the local production of routinely used SPECT tracers such as 67 Ga, 201 Tl, 123 I, and 111 In, but also sparkled the initiation of research and development of various radionuclides such as copper radionuclides, 68 Ge, 103 Pd, 9 and 57 Co in some member states also with the help of the IAEA. Furthermore, many member states have been successful in the production and formulation of therapeutic radiopharmaceuticals with reactors with the help of IAEA coordinated research and technical cooperation projects.
Discussion
The average number of gamma cameras including SPECT/CT systems per million people in the region is 2.3, with a range of 0.1 in Iraq to 10.3 in Kuwait and 10.8 in Israel. This is lower than the average ratio in Latin America of 2.6, 10 Europe 5.57, Canada 20.35, 11 and USA 47. 2. 12 The availability of PET/CT in the region is one scanner per 2.04 million people, and relative to the population, Lebanon (2.2) followed by Kuwait (1.7) have the highest number of scanners per million people. Recommendations provided in literature that takes into account global, nonspecific data, suggests that the number of scanners should be 1.0-1.5 per million inhabitants. 13 In a well-developed context, expectations are that this figure would rise to 2.0-2.5 scanners per million population. 14 It becomes increasingly evident that there is room for growth and development in the region to install more PET/CT scanners and keep up with the support needed to address the high incidence of NCDs.
Regarding the general status of NM in the Middle East, the wide-range availability of almost all current diagnostic and therapeutic applications is recognized as a strength. The growth in technology and human resources provides a strong incentive for further consolidation of the specialty and expansion of services provided.
The fact that the vast majority of NM centers belong to the public healthcare sector underlines the governmental support and acknowledges the importance of clinical applications of NM.
Even though training programs at university level are available in some countries for all the professional disciplines involved in the practice of NM, for example, NM physicians, medical physicists, radiopharmacists or radiochemists, and technologists, there is a clear need of expanding the coverage and establishing new academic programs to cover the needs of the region and enable further growth. Intraregional initiatives, such as the establishment of the Arabic Society of Nuclear Medicine, could provide strong incentives towards strengthening the training programs in the region. The fact that some countries have very advanced status of NM practice provides an additional strong argument in support of regional cooperation.
Research and overall development activities in the Middle East are clear indicators of the advancements in NM that the countries have made. However, we acknowledge that some countries in the region have still not acquired important NM technologies, such as cyclotrons and PET/CT scanners, and efforts should be made to mobilize all stakeholders at national, regional, and international level to strengthen the resources and enable further growth of this medical specialty.
Conclusion
Countries in the Middle East have witnessed an important growth of NM in the past decades. Although there are profound differences in the region regarding the availability Table 7 List of Available Therapeutic Agents in the Region, Data Obtained From Nuclear Medicine Professionals of human as well as technical capacities, it is also evident that the practice of this medical specialty has seen an overall advancement. This is reflected in the general availability of current NM diagnostic and therapeutic procedures, as well as the ever growing number of technologies installed. However, there is a shortage of well-structured training at academic institutions in the region, and there is a need to establish and expand training programs for all disciplines involved in the specialty. Furthermore, we note that PET/CT is still not available in some countries of the region. Also, there is a need for further raising of awareness of the usefulness of clinical applications of NM techniques. Addressing these limiting factors, along with strengthening intraregional and international cooperation, would enable further growth and upscaling of NM in the Middle East, which is of utmost importance in the wake of the growing incidence of NCDs in the region.
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